On this page
PharmEasy parent API Holdings cuts FY26 loss 67% to ₹520 Cr as operating revenue grows 12.7%
Our read
PharmEasy's parent will more likely than not stay EBITDA-positive through FY27 with growth near 10%, but the margin cushion is thin.
For operators
API Holdings' Q1 FY27 gross margin of 21.4% and EBITDA of ₹39.3 Cr on ₹1,754 Cr revenue show a scaled pharmacy platform can run near breakeven, and with PharmEasy B2C at ₹348 Cr, about a fifth of the total, most of the growth is coming from outside the consumer app.
Watch
EBITDA above Q1 FY27's ₹39.3 Cr in the Q2 FY27 results would mean the profit turn is holding, easing pressure on lenders and distributors.
The report,
API Holdings, PharmEasy's parent, cut its FY26 consolidated net loss by 67% to ₹520 Cr from ₹1,572 Cr, while operating revenue grew 12.7% to ₹6,618.5 Cr. Q1 FY27 revenue rose 10% to ₹1,754 Cr with EBITDA of ₹39.3 Cr.
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
Reported figures
From the report. Source details below
| Q1 FY27 PharmEasy B2C revenue: | ₹348 Cr |
|---|---|
| Q1 FY27 gross margin: | 21.4% |
Why it matters to operators and investors
With operating revenue of ₹6,618.5 Cr, a loss that has narrowed to ₹520 Cr and positive EBITDA, API Holdings looks a more credible partner or target than a year ago, though the remaining loss will still weigh on any valuation talks.
What to watch next
- Gross margin against Q1 FY27's 21.4%
- PharmEasy B2C revenue against Q1's ₹348 Cr
- Any refinancing or fundraise announcement by API Holdings
- Discounting moves from Tata 1mg or Apollo 24/7
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- API Holdings is likely to keep prioritising EBITDA and cash discipline over aggressive growth, with revenue growth staying near 10%.
- PharmEasy may lean on its B2C business to lift gross margin from 21.4%, rather than buying volume with discounts.
- Lenders and investors are likely to read the cut in net loss from ₹1,572 Cr to ₹520 Cr as a basis to extend or refinance debt on easier terms.
- Rivals such as Tata 1mg and Apollo 24/7 may respond with sharper discounts and faster delivery in key metros if PharmEasy's B2C revenue gains pace.
- Expect API Holdings to point to its first quarters of positive EBITDA as it talks to suppliers, partners and future investors.